Celldex Therapeutics (NASDAQ:CLDX) Trading Down 8.5% - Here's Why

Key Points

• Celldex shares fell 8.5% to about $30.65 despite an 87% increase in trading volume, likely reflecting profit-taking and lingering investor concerns following the company’s clinical update.
• Barzolvolimab met the primary and key secondary endpoints in two Phase 3 trials for chronic spontaneous urticaria, with benefits sustained through 24 weeks; Celldex expects to submit a biologics license application in 2027.
• Analysts broadly remain bullish, with several raising price targets and the stock carrying a “Moderate Buy” consensus, but safety concerns and heavy cash burn remain important risks.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) fell 8.5% on Wednesday . The company traded as low as $30.76 and last traded at $30.6490. Approximately 1,895,097 shares traded hands during trading, an increase of 87% from the average daily volume of 1,012,472 shares. The stock had previously closed at $33.51.

Trending Headlines about Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: Barzolvolimab met all major trial objectives. Celldex reported that its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 studies met their primary and key secondary endpoints in chronic spontaneous urticaria. The drug showed meaningful benefits, including in patients who had not responded adequately to omalizumab and those with severe disease or angioedema. Efficacy was sustained or improved through 24 weeks, and the company expects to submit a biologics license application in 2027. Celldex Phase 3 results
• Positive Sentiment: Analysts raised their valuation estimates. Leerink Partners increased its price target to $88 and assigned an “outperform” rating. Morgan Stanley raised its target to $57 and rated the stock “overweight,” while Cantor Fitzgerald lifted its target to $72 and HC Wainwright raised its target to $64 with a “buy” rating. These revisions indicate that analysts see substantial commercial potential for barzolvolimab.
• Neutral Sentiment: The market reaction was driven by expectations as well as fundamentals. The positive readout was a major anticipated catalyst, potentially encouraging profit-taking after the announcement. Celldex will continue both studies through 52 weeks, leaving additional follow-up data and regulatory execution as important catalysts.
• Negative Sentiment: Safety concerns tempered enthusiasm. Reports said investors remained concerned about the treatment’s safety profile despite management’s description of barzolvolimab as well tolerated through 24 weeks. Analysts have argued that these concerns may be misplaced, but the issue remains a source of volatility. Safety concerns report
• Negative Sentiment: Celldex’s heavy cash burn remains a longer-term risk. Coverage has questioned whether the company can fund development and commercialization without raising additional capital, a concern for a loss-making biotechnology company with substantial future spending needs. Celldex cash-burn analysis

Analyst Ratings Changes

CLDX has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Celldex Therapeutics from a "strong sell" rating to a "sell" rating in a research report on Sunday, July 12th. Canaccord Genuity Group decreased their price target on Celldex Therapeutics from $62.00 to $60.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. Morgan Stanley raised their price target on Celldex Therapeutics from $50.00 to $57.00 and gave the stock an "overweight" rating in a research report on Wednesday. Cantor Fitzgerald boosted their price objective on Celldex Therapeutics from $61.00 to $72.00 and gave the company an "overweight" rating in a report on Tuesday. Finally, HC Wainwright increased their target price on Celldex Therapeutics from $42.00 to $64.00 and gave the stock a "buy" rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $61.92.

Celldex Therapeutics Stock Performance

The company has a market cap of $2.42 billion, a price-to-earnings ratio of -7.10 and a beta of 0.84. The business has a 50-day simple moving average of $39.03 and a 200-day simple moving average of $34.84.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $0.12. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.73 million. Research analysts anticipate that Celldex Therapeutics, Inc. will post -4.17 EPS for the current year.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CLDX. Nykredit A S acquired a new stake in Celldex Therapeutics during the second quarter worth approximately $67,000. Diversified Trust Co purchased a new position in shares of Celldex Therapeutics in the 1st quarter valued at $223,000. Walleye Capital LLC acquired a new stake in Celldex Therapeutics during the 1st quarter worth $258,000. Amundi purchased a new stake in Celldex Therapeutics in the first quarter valued at $297,000. Finally, Glenmede Trust Co. NA acquired a new position in Celldex Therapeutics in the first quarter valued at $357,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for diseases with significant unmet medical needs. The company's research programs address conditions in immunology, inflammation, oncology and other areas where targeted immune-system modulation may provide therapeutic benefits.

Celldex's lead investigational product is barzolvolimab, an antibody designed to block the KIT receptor and reduce mast cells. The therapy is being studied in immune-mediated diseases, including chronic spontaneous urticaria and prurigo nodularis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.